ClinicalTrials.gg

Program

QL2109

A development code.

Its studies are mostly in Multiple Myeloma · Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 3, since Dec 16, 20243 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical33 open or runningphase 3since Dec 16, 2024Apr 14, 2024Dec 2027phase 3 · NCT06742138

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2024First study: phase 1 study in NeoplasmsFirst studyNCT06371534 · 228 planned · China
  2. Dec 16, 2024Phase 3 study in Multiple MyelomaNCT06742138 · 284 planned
  3. Feb 3, 2026Phase 1 study in Multiple MyelomaNCT07400744 · 102 planned

Ahead

  1. Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT06742138

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07400744Multiple Myeloma1Not yet recruitingSep 2026102
NCT06742138Multiple Myeloma3Not yet recruitingDec 2027284
NCT06371534Neoplasms · China1RecruitingApr 2025228

How it is read

Names in the registry

  • “QL2109”, 3 entries

Codes read as this program: QL2109.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.